Comparison of resazurin microtiter assay performance and BACTEC MGIT 960 in the susceptibility testing of Brazilian clinical isolates of Mycobacterium tuberculosis to four first-line drugs

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual de Maringá (UEM)
dc.contributorInstituto Clemente Ferreira
dc.date.accessioned2014-05-20T13:25:05Z
dc.date.available2014-05-20T13:25:05Z
dc.date.created2014-05-20T13:25:05Z
dc.date.issued2013-01-01
dc.identifierBrazilian Journal of Microbiology. Sociedade Brasileira de Microbiologia, v. 44, n. 1, p. 281-285, 2013.
dc.identifier1517-8382
dc.identifierhttp://hdl.handle.net/11449/7937
dc.identifier10.1590/S1517-83822013005000028
dc.identifierS1517-83822013000100041
dc.identifierWOS:000323575600041
dc.identifierS1517-83822013000100041.pdf
dc.identifier2114570774349859
dc.description.abstractWe assessed the performance of REMA in comparison with BACTEC MGIT 960 in the susceptibility testing of 80 Mycobacterium tuberculosis clinical isolates from Clemente Ferreira Institute against four drugs. REMA proved to be a rapid and accurate method, providing excellent correlation with BACTEC MGIT 960, with the exception of results for the ethambutol drug.
dc.languageeng
dc.publisherSociedade Brasileira de Microbiologia
dc.relationBrazilian Journal of Microbiology
dc.relation1.810
dc.relation0,630
dc.rightsAcesso aberto
dc.sourceSciELO
dc.subjectMycobacterium tuberculosis
dc.subjecttuberculosis
dc.subjectdrug susceptibility testing
dc.titleComparison of resazurin microtiter assay performance and BACTEC MGIT 960 in the susceptibility testing of Brazilian clinical isolates of Mycobacterium tuberculosis to four first-line drugs
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución